Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spesolimab phase IIa trial in fibrostenotic Crohn's disease
NL-OMON51041Phase 2Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Crohn's disease comparing Spesolimab plus optimized background therapy with Placebo plus optimized background therapy (2 arms). Primary endpoints: Maintained Symptomatic Stenosis Response at Week 48 and Radiographic Stenosis Response at Week 48. Started Nov 2021; status: active, not recruiting.
02
Drugs
spesolimab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON51041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51041.